Picking Up The Pieces Of “Cures”: Senate Process Resets Focus On 2017
This article was originally published in RPM Report
The Senate Health Committee is planning a series of legislative mark-ups for 2016 billed as the companion process to the House “21st Century Cures” process. The real message is that Cures won’t move in 2016 – but the work should carry over to the user fee process in 2017.
You may also be interested in...
The recent series of sales of priority review vouchers at ever-higher prices has transformed what had seemed to be a failed incentive model into a hot topic. However, one key stakeholder is not celebrating the recent developments: the FDA review teams that have to deliver the faster paced reviews continue to have strong reservations about the program.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.